Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Photochemotherapy | 22 | 2026 | 46 | 8.460 |
Why?
|
| Mouth Neoplasms | 7 | 2026 | 42 | 4.060 |
Why?
|
| Photosensitizing Agents | 14 | 2026 | 32 | 3.760 |
Why?
|
| Pancreatic Neoplasms | 8 | 2024 | 354 | 3.640 |
Why?
|
| Protoporphyrins | 6 | 2026 | 9 | 3.120 |
Why?
|
| Aminolevulinic Acid | 8 | 2026 | 9 | 3.050 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2026 | 264 | 2.450 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2024 | 128 | 2.420 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2024 | 218 | 1.870 |
Why?
|
| Cell Line, Tumor | 23 | 2026 | 1573 | 1.610 |
Why?
|
| Models, Biological | 9 | 2020 | 1193 | 1.550 |
Why?
|
| Stromal Cells | 2 | 2024 | 78 | 1.450 |
Why?
|
| Low-Level Light Therapy | 3 | 2026 | 12 | 1.330 |
Why?
|
| Extracellular Matrix | 4 | 2024 | 148 | 1.310 |
Why?
|
| Rheology | 5 | 2020 | 84 | 1.180 |
Why?
|
| Optical Imaging | 2 | 2025 | 77 | 1.010 |
Why?
|
| Coculture Techniques | 2 | 2024 | 104 | 1.000 |
Why?
|
| Smartphone | 4 | 2023 | 75 | 0.880 |
Why?
|
| Fibroblasts | 2 | 2024 | 423 | 0.870 |
Why?
|
| Cell Communication | 1 | 2024 | 135 | 0.810 |
Why?
|
| Gastric Mucins | 3 | 2009 | 3 | 0.790 |
Why?
|
| Ovarian Neoplasms | 8 | 2013 | 170 | 0.720 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 644 | 0.700 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 289 | 0.690 |
Why?
|
| Cell Survival | 10 | 2026 | 588 | 0.670 |
Why?
|
| Porphyrins | 5 | 2022 | 10 | 0.670 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2015 | 300 | 0.620 |
Why?
|
| Riboflavin | 1 | 2020 | 18 | 0.610 |
Why?
|
| Neoplasms | 5 | 2019 | 1376 | 0.570 |
Why?
|
| Nanoparticles | 2 | 2022 | 551 | 0.550 |
Why?
|
| Light | 2 | 2018 | 195 | 0.540 |
Why?
|
| Cell Culture Techniques | 6 | 2014 | 195 | 0.530 |
Why?
|
| Microscopy | 3 | 2014 | 99 | 0.500 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 183 | 0.460 |
Why?
|
| MicroRNAs | 1 | 2022 | 714 | 0.460 |
Why?
|
| Humans | 30 | 2026 | 65632 | 0.430 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2014 | 44 | 0.430 |
Why?
|
| Cell Movement | 1 | 2016 | 482 | 0.420 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 80 | 0.390 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 367 | 0.390 |
Why?
|
| Mice, Nude | 3 | 2025 | 287 | 0.390 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2019 | 84 | 0.360 |
Why?
|
| Deoxycytidine | 1 | 2011 | 45 | 0.340 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 42 | 0.340 |
Why?
|
| Molecular Imaging | 1 | 2010 | 52 | 0.300 |
Why?
|
| Mucus | 1 | 2009 | 17 | 0.300 |
Why?
|
| Gastric Mucosa | 1 | 2009 | 53 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2024 | 858 | 0.290 |
Why?
|
| Helicobacter pylori | 1 | 2009 | 58 | 0.290 |
Why?
|
| Phase Transition | 1 | 2007 | 23 | 0.250 |
Why?
|
| Lasers | 2 | 2024 | 38 | 0.230 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2025 | 94 | 0.230 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2024 | 2 | 0.220 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2024 | 4 | 0.220 |
Why?
|
| Animals | 8 | 2025 | 21450 | 0.210 |
Why?
|
| Phantoms, Imaging | 1 | 2025 | 239 | 0.210 |
Why?
|
| Mice | 4 | 2025 | 11172 | 0.190 |
Why?
|
| Spheroids, Cellular | 2 | 2014 | 28 | 0.190 |
Why?
|
| Carboplatin | 3 | 2011 | 47 | 0.180 |
Why?
|
| Swine | 3 | 2009 | 397 | 0.180 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2022 | 152 | 0.180 |
Why?
|
| Cell Proliferation | 3 | 2016 | 1042 | 0.170 |
Why?
|
| Printing, Three-Dimensional | 1 | 2019 | 42 | 0.150 |
Why?
|
| Protein Corona | 1 | 2019 | 10 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2022 | 5818 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2019 | 65 | 0.140 |
Why?
|
| Blood Proteins | 1 | 2019 | 84 | 0.140 |
Why?
|
| Optical Fibers | 1 | 2018 | 11 | 0.140 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 446 | 0.140 |
Why?
|
| Models, Genetic | 1 | 2019 | 267 | 0.140 |
Why?
|
| Developing Countries | 1 | 2018 | 87 | 0.130 |
Why?
|
| Microscopy, Confocal | 4 | 2010 | 240 | 0.130 |
Why?
|
| Viscosity | 2 | 2009 | 60 | 0.130 |
Why?
|
| Elasticity | 2 | 2009 | 46 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 285 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2009 | 465 | 0.120 |
Why?
|
| Female | 13 | 2019 | 34294 | 0.120 |
Why?
|
| Cerium | 1 | 2016 | 2 | 0.120 |
Why?
|
| Metal Nanoparticles | 1 | 2019 | 191 | 0.120 |
Why?
|
| Radiation-Protective Agents | 1 | 2016 | 9 | 0.120 |
Why?
|
| Mesoderm | 1 | 2016 | 89 | 0.120 |
Why?
|
| Phenotype | 1 | 2019 | 1235 | 0.110 |
Why?
|
| Electric Power Supplies | 1 | 2015 | 6 | 0.110 |
Why?
|
| Lighting | 1 | 2015 | 14 | 0.110 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 77 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 526 | 0.100 |
Why?
|
| Holography | 1 | 2014 | 1 | 0.100 |
Why?
|
| Cell Membrane Permeability | 1 | 2014 | 40 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2013 | 15 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 426 | 0.100 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 28 | 0.100 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 31 | 0.100 |
Why?
|
| Thiazines | 1 | 2011 | 2 | 0.090 |
Why?
|
| bcl-X Protein | 1 | 2011 | 24 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 48 | 0.090 |
Why?
|
| Computational Biology | 1 | 2013 | 368 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 1715 | 0.080 |
Why?
|
| Optical Phenomena | 1 | 2010 | 8 | 0.080 |
Why?
|
| Time-Lapse Imaging | 1 | 2010 | 21 | 0.080 |
Why?
|
| Software | 1 | 2014 | 401 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2010 | 37 | 0.080 |
Why?
|
| Proteoglycans | 1 | 2010 | 34 | 0.080 |
Why?
|
| Laminin | 1 | 2010 | 81 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 53 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2011 | 611 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 167 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 588 | 0.080 |
Why?
|
| Cell Nucleolus | 1 | 2010 | 71 | 0.080 |
Why?
|
| Collagen | 1 | 2010 | 135 | 0.080 |
Why?
|
| Cytological Techniques | 1 | 2009 | 27 | 0.080 |
Why?
|
| Fluoresceins | 1 | 2009 | 31 | 0.080 |
Why?
|
| Urease | 1 | 2009 | 10 | 0.080 |
Why?
|
| Urea | 1 | 2009 | 42 | 0.070 |
Why?
|
| Algorithms | 1 | 2014 | 1051 | 0.070 |
Why?
|
| Hydrogels | 1 | 2009 | 127 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 401 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 466 | 0.070 |
Why?
|
| Mitochondria | 1 | 2011 | 413 | 0.070 |
Why?
|
| Osmolar Concentration | 1 | 2007 | 91 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 1233 | 0.060 |
Why?
|
| Gels | 1 | 2007 | 78 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 876 | 0.060 |
Why?
|
| Apoptosis | 1 | 2011 | 1100 | 0.060 |
Why?
|
| Peptides | 1 | 2009 | 593 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 741 | 0.050 |
Why?
|
| Brazil | 1 | 2022 | 104 | 0.040 |
Why?
|
| Cadherins | 2 | 2013 | 90 | 0.040 |
Why?
|
| India | 1 | 2022 | 165 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2024 | 301 | 0.040 |
Why?
|
| Cell Death | 2 | 2013 | 289 | 0.040 |
Why?
|
| Optics and Photonics | 1 | 2020 | 13 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2011 | 223 | 0.040 |
Why?
|
| Biophysical Phenomena | 1 | 2020 | 23 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2019 | 27 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2024 | 2189 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 181 | 0.030 |
Why?
|
| Time Factors | 1 | 2005 | 3776 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 65 | 0.030 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2015 | 3 | 0.030 |
Why?
|
| Carbonic Anhydrases | 1 | 2015 | 6 | 0.030 |
Why?
|
| Semiconductors | 1 | 2015 | 14 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2015 | 79 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 77 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 237 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 23 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 373 | 0.030 |
Why?
|
| Ascites | 1 | 2013 | 22 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2013 | 16 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2013 | 108 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2013 | 128 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 391 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 42 | 0.020 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2010 | 20 | 0.020 |
Why?
|
| Fibronectins | 1 | 2010 | 44 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2010 | 102 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 142 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 233 | 0.020 |
Why?
|
| Liposomes | 1 | 2010 | 117 | 0.020 |
Why?
|
| Epitopes | 1 | 2010 | 291 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 664 | 0.020 |
Why?
|
| Adult | 1 | 2019 | 17507 | 0.010 |
Why?
|
| Middle Aged | 1 | 2019 | 18431 | 0.010 |
Why?
|
| Male | 1 | 2019 | 31281 | 0.010 |
Why?
|